Big Moving Stock chart patterns and volume.
The Hot Industries
CATV Systems 2
Specialty Chemicals 2
Chemicals - Major Diversified 2
The Hot Sectors
Basic Materials 4
ARIA Ariad Pharmaceuticals Inc.
ARIAD Pharmaceuticals, Inc., an oncology company, focuses on the discovery, development, and commercialization of medicines for cancer patients. The company focuses on commercializing Iclusig (ponatinib), a cancer medicine; and developing additional molecularly targeted therapies to treat patients with blood cancers and solid tumors. Iclusig is a tyrosine kinase inhibitor (TKI) that is approved in the United States for the treatment of adult patients with chronic, accelerated, or blast phase chronic myeloid leukemia, who are resistant or intolerant to prior TKI therapy, as well as for the treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia, who are resistant or intolerant to prior TKI therapy. Its product pipeline consists of AP26113, an investigational dual inhibitor of anaplastic lymphoma kinase, which is being studied in a phase I/II clinical trial in patients with advanced solid tumors comprising non-small cell lung cancer; Ridaforolimus, an investigational mTOR inhibitor, which is being studied in multiple clinical trials in patients with various types of cancers; and AP1903, a small-molecule dimerizer drug. The company sells and markets Iclusig through specialty pharmacies and specialty distributors in the United States. It has collaboration and license agreement with Merck & Co., Inc. for the development, manufacture, and commercialization of ridaforolimus, for use in cancer; and license agreements with Medinol Ltd. and ICON Medical Corp. to develop and commercialize stents and other medical devices to deliver ridaforolimus. ARIAD Pharmaceuticals, Inc. was founded in 1991 and is headquartered in Cambridge, Massachusetts.
Close encounters of the Amazon kind2 Mar 2015, 9:07 amThere are two surprising things about anacondas, apart from the fact that they can probably swallow a human whole. The first is that they give birth to live young, as many as 40 at one time. The second is that it takes three men to carry one. I am introduced to this fun fact on the first day of my Amazon River cruise aboard the luxury riverboat the MV Aria.
Arista, Novo Nordisk, Ann, Noodles and Newmont Mining are big market movers20 Feb 2015, 4:22 pmNEW YORK, N.Y. - Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market: NYSE Arista Networks Inc. (ANET), up 51 cents to $68.50 The data networking company reported better-than-expected fourth-quarter financial results and a positive ...
Call buyers coming back to Ariad20 Feb 2015, 9:32 amTraders are looking for Ariad Pharmaceuticals to continue rising as investor activism heats up. More than 3,000 May 10 calls were purchased this morning for $0.30 and $0.35, according to optionMONSTER's ...
ARIAD (ARIA) Posts Narrower-than-Expected Q4 Loss - Tale of the Tape19 Feb 2015, 7:05 amARIAD (ARIA) Posts Narrower-than-Expected Q4 Loss
Ariad reports 4Q loss19 Feb 2015, 6:43 amOn a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 3 cents. The results exceeded Wall Street expectations. The average estimate of analysts surveyed by Zacks Investment ...
Will ARIAD (ARIA) Impress on Iclusig Sales this Earnings? - Analyst Blog18 Feb 2015, 8:40 amARIAD Pharmaceuticals (ARIA) is set to report fourth-quarter 2014 results on Feb 19.
Why Ariad Pharmaceuticals (ARIA) Might Surprise This Earnings Season - Tale of the Tape18 Feb 2015, 6:33 amAriad Pharmaceuticals (ARIA) looks poised to beat analyst estimates this earnings season, with a favourable Zacks Rank and an ESP in positive territory.
Ariad Pharmaceuticals (ARIA) Jumps: Stock Moves Up 6.6% - Tale of the Tape17 Feb 2015, 6:51 amAriad Pharmaceuticals Inc. (ARIA) was a big mover last session, as the company saw its shares rise nearly 7% on the day.
Will NPS Pharmaceuticals (NPSP) Miss on Earnings in Q4? - Analyst Blog16 Feb 2015, 11:00 amNPS Pharmaceuticals (NPSP), which is expected to report fourth-quarter 2014 results on Feb 17, had posted a negative earnings surprise of 300% in the last quarter.
Will Immune Design (IMDZ) Miss on Earnings This Season? - Analyst Blog10 Feb 2015, 12:40 pmImmune Design (IMDZ) is expected to report fourth-quarter 2014 results on Feb 11, 2015 and holds a Zacks Rank #4 (Sell) with an Earnings ESP of 0.00%.